With News of New Strain Spreading, NanoViricides, Inc. (NYSE American: NNVC) Needs to be #1 on Tomorrow's Watchlist

There's No Time to Waste - Get Ready Now!

Coming Off Our Recent Biotech Profile That Saw An Approximate 144% Move In Under 4 Sessions, You Need To Immediately Turn Your Attention To NanoViricides, Inc. (NYSE American: NNVC)! NanoViricides, Inc. (NYSE American: NNVC) Comes Backed by Several Potential Catalysts Including: Low Float: With A Small Float Of Less Than 11.3M Shares Available To The Public, NanoViricides, Inc. (NYSE American: NNVC) Could Be Poised For Potential Volatility And Significant Movement If Demand Begins To Shift! Higher Potential For Growth: With A Market Cap Under $30M, NanoViricides, Inc. (NYSE American: NNVC) Might Have Flown Under Wall Street's Radar—Until Now.The Growth Potential Here Could Be Substantial As The Market Catches On! Strong Bullish Signals: Technical Analysis Is Flashing Strong Buy Signals, With Barchart Triggering A Perfect Score Of 13 Out Of 13 Bullish Indicators And TradingView Showing Bullish Signals On 16 Indicators! Cutting-Edge Technology: NanoViricides, Inc. (NYSE American: NNVC) Is Pioneering A Novel Nanomedicine Platform Designed To Combat A Wide Range Of Viruses By Mimicking Host Cells And Dismantling Virus Particles! Broad Pipeline: NanoViricides, Inc. (NYSE American: NNVC) Is Developing Multiple Dr-ug Candidates Targeting High-Impact Viruses, Including Influenza, H-I-V, Dengue, And Ebola, With A Potential Market Size Of $40 To $70B! Addressing Viral Resistance: NV-387's Unique Design Could Overcome One Of The Biggest Challenges In Antiviral Therapeutics—Preventing The Rapid Development Of Viral Resistance, A Common Issue With Current Treatments! Advancing Toward FDA Approval: NanoViricides Is Progressing With Its Clinical Trials, Particularly For Its Lead Candidate NV-387, Positioning Itself To Move Closer To FDA Submissions And Potential Regulatory Approval! Do Not Miss Out on NanoViricides, Inc. (NYSE American: NNVC)! August 18, 2024 Dear Reader, Immediately turn your attention to NanoViricides, Inc. (NYSE American: NNVC). As the World Health Organization reinstates M-pox (“MPX”) as a public health emergency due to a severe strain spreading in Africa, the need for effective antiviral solutions has never been more urgent.  NanoViricides, Inc. (NYSE American: NNVC) stands out as a company with the potential to tackle this challenge head-on.  Now is the time to start your research on NanoViricides, Inc. (NYSE American: NNVC) before the rest of the market catches on. You see, like our recent biotech profile that moved approximately 144% in under 4 sessions, NanoViricides, Inc. (NYSE American: NNVC) also has a very low float with less than 11.3M shares available to the public. Before you miss out on a hidden gem, keep reading to discover why NanoViricides, Inc. (NYSE American: NNVC) deserves the top spot on your radar.  With a market cap under $30M, this company may have flown under Wall Street's radar, but with a perfect score of 13/13 Bullish Indicators on Barchart and 16 Bullish Signals on TradingView as of Friday’s close, it’s time for you to put NanoViricides, Inc. (NYSE American: NNVC) #1 on tomorrow’s watchlist.  Keep reading to see why you cannot miss out on NanoViricides, Inc. (NYSE American: NNVC). NanoViricides, Inc. (NYSE American: NNVC) is a pioneering force in the development of cutting-edge nanomedicine dr-ugs designed to combat a wide array of viruses.  Their revolutionary nanoviricide® platform represents a breakthrough in antiviral treatment, offering a unique mechanism that goes beyond traditional antibodies and immunotherapies. By mimicking host cells, nanoviricides are engineered to dismantle virus particles, effectively blocking reinfection and delivering targeted antiviral payloads to infected cells without harming healthy ones. This innovative approach positions NanoViricides, Inc. (NYSE American: NNVC) as a leader in the fight against viral threats. With their own state-of-the-art cGMP manufacturing facility, NanoViricides has the capability to produce large-scale dr-ug substances and products, significantly reducing development costs and timelines.  One of their lead candidates, NV-HHV-101, is on the brink of entering human clinical trials as a topical treatment for shingles, with promising potential for expansion into other indications within the HerpeCide™ program.  This program alone targets a market exceeding $10B, with NV-HHV-101 estimated to tap into a $0.5B to $2B market. Beyond her-pes-related treatments, NanoViricides, Inc. (NYSE American: NNVC) is developing dr-ug candidates against a broad spectrum of viruses, including influenza, H-I-V, Den-gue, and Eb-ola, targeting a market worth $40 to $70B.  Their "bind-encapsulate-destroy" technology offers a powerful solution against viral mutations, making dr-ug resistance unlikely. With a robust intellectual property portfolio and collaborations with leading researchers, NanoViricides, Inc. (NYSE American: NNVC) is advancing rapidly towards FDA submissions, aiming to bring their first groundbreaking treatment to market. This unique combination of innovative technology, strong intellectual property, and advanced dr-ug development positions NanoViricides, Inc. as a company poised to make a significant impact on global health. NanoViricides, Inc. (NYSE American) recently provided a significant update on its clinical program and strategy. The company's leading candidate, NV-387, is poised to potentially transform the landscape of antiviral treatment, similar to how antibiotics revolutionized bacterial infection management. A Revolutionary Approach to Antiviral Therapy NanoViricides is at the forefront of developing a novel class of direct-acting antiviral dr-ugs designed to disable virus particles before they can infect host cells. NV-387, their first clinical-stage dr-ug, mimics the properties of sulfated-proteoglycans (S-PGs), which over 90% of pathogenic human viruses use to infect human cells. This innovative mechanism positions NV-387 as a potentially groundbreaking broad-spectrum antiviral, offering an ultra-broad spectrum of activity akin to the impact penicillin had on bacterial infections. Preclinical Success: Efficacy Across Multiple Virus Classes The company's non-clinical animal trials have demonstrated NV-387's effectiveness across several major classes of viruses, including Influenza, Respiratory Syncytial Virus (RSV), and orthopoxviruses like Sm-allp-ox and MPX. In particular, NV-387 showed remarkable results in an RSV efficacy study, where it completely protected lethally lung-infected mice, offering full lung protection—a result that indicates potential curative properties. This is especially noteworthy since no current approved dr-ug effectively treats RSV once the infection has established itself. Addressing the "Triple-demic" and Beyond NV-387’s effectiveness against the so-called "triple-demic" respiratory viruses—Influenza, and RSV—highlights its potential to address a significant market need. Together, these viruses represent an estimated $8B market in 2024, with expectations of growth to $12B within three years. However, the scope of NV-387 extends far beyond these three viruses. The dr-ug is expected to be effective against a wide range of viruses, including Den-gue, Zika, Yellow Fever, West Nile, Rabies, Ebola, and many others. This broad-spectrum effectiveness makes NV-387 a potential game-changer in the antiviral market. Preventing Viral Resistance One of the most critical challenges in antiviral therapeutics is the rapid development of viral resistance to existing medical countermeasures (MCMs) such as vaccines, antibodies, and small-molecule antivirals. Unlike these conventional approaches, NV-387 is designed in a way that makes it highly unlikely for viruses to develop substantial resistance. This unique attribute could position NV-387 as a solution to one of the most significant hurdles in modern antiviral treatment. Clinical Trials and Future Directions NanoViricides is actively progressing with its clinical program for NV-387. The company is completing a database audit of its Phase 1a/1b human clinical trial in healthy subjects in India. Following this, the data will undergo a rigorous external technical audit, after which the database will be analyzed to evaluate NV-387's safety and tolerability across different dosage regimens. The results will contribute to the final Phase I clinical trial report. In parallel, preparations for a Phase II clinical trial are underway, focusing on evaluating NV-387's antiviral effectiveness in humans. The broad-spectrum nature of NV-387 opens the door for a novel, adaptive clinical trial design that could assess the dr-ug's effectiveness against multiple respiratory viruses in a single study. Such an approach could provide rapid insights into which viruses NV-387 targets most effectively, thereby accelerating the path to regulatory approval and market entry. NanoViricides is also developing a more traditional Phase II clinical trial, with an initial focus on gaining regulatory approval for the treatment of pediatric RSV disease. The company plans to submit a Pre-IND application with the U.S. FDA, or similar advice-seeking applications in other regulatory regions, to guide the further development of NV-387. Strategic Collaborations and Future Outlook Building on the significant progress made in FY 2024, NanoViricides is strategically positioning itself for further advancements in the coming year. The company has initiated outreach efforts to secure collaborations with major pharmaceutical companies, which could accelerate the development and commercialization of NV-387. These partnerships could also provide the necessary financing to bring this potentially revolutionary antiviral dr-ug to market. NanoViricides, Inc. (NYSE American: NNVC) is making substantial strides in developing NV-387, a dr-ug with the potential to revolutionize antiviral treatment. If successful, NV-387 could become the go-to treatment for a wide array of viral infections, much like how antibiotics became indispensable in treating bacterial infections. As the company advances through clinical trials and seeks strategic partnerships, NV-387 could soon become a vital tool in the global fight against viral diseases. 7 reasons why NanoViricides, Inc. (NYSE American: NNVC) needs to be #1 on Monday’s watchlist… 1. Low Float: With a small float of less than 11.3M shares available to the public, NanoViricides, Inc. (NYSE American: NNVC) could be poised for potential volatility and significant movement if demand begins to shift. 2. Higher Potential for Growth: With a market cap under $30M, NanoViricides, Inc. (NYSE American: NNVC) might have flown under Wall Street's radar—until now. The growth potential here could be substantial as the market catches on. 3. Strong Bullish Signals: Technical analysis is flashing strong buy signals, with Barchart triggering a perfect score of 13 out of 13 bullish indicators and TradingView showing bullish signals on 16 indicators. 4. Cutting-Edge Technology: NanoViricides, Inc. (NYSE American: NNVC) is pioneering a novel nanomedicine platform designed to combat a wide range of viruses by mimicking host cells and dismantling virus particles. 5. Broad Pipeline: NanoViricides, Inc. (NYSE American: NNVC) is developing multiple dr-ug candidates targeting high-impact viruses, including influenza, H-I-V, Den-gue, and Ebola, with a potential market size of $40 to $70B. 6. Addressing Viral Resistance: NV-387's unique design could overcome one of the biggest challenges in antiviral therapeutics—preventing the rapid development of viral resistance, a common issue with current treatments. 7. Advancing Toward FDA Approval: NanoViricides is progressing with its clinical trials, particularly for its lead candidate NV-387, positioning itself to move closer to FDA submissions and potential regulatory approval. NanoViricides, Inc. (NYSE American: NNVC) is a company that demands immediate attention. With a small float of less than 12M shares, the company could be set for potential volatility and significant price movement if demand begins to shift. Despite its market cap being under $30M, the growth potential is considerable, especially if more eyes begin to turn toward it. The technical indicators are compelling, with Barchart showing a perfect score on 13 out of 13 bullish signals and TradingView indicating 16 bullish signals. NanoViricides, Inc. (NYSE American: NNVC) is at the forefront of antiviral treatment innovation, using a cutting-edge nanomedicine platform to target and dismantle a wide array of viruses. Their broad pipeline, advanced clinical trials, and strategic collaborations suggest that NanoViricides, Inc. (NYSE American: NNVC) is poised to make a significant impact on the antiviral market. With the potential to revolutionize the fight against viral diseases, particularly with their lead candidate NV-387, now is the time to start your research on NanoViricides, Inc. (NYSE American: NNVC). Could this be the breakthrough company that makes a difference? Make sure NanoViricides, Inc. (NYSE American: NNVC) is #1 on tomorrow’s watchlist. Do not wait on this one. Pull up (NNVC) right now and start your research. I’ll check back early tomorrow morning. Have a good night. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends (stocknewstrends . com) is owned by TD Media LLC, a limited liability company. Disclosure: I am not a fin-an-cial adviser. All potential percentage gains are based on from the low to the high of day. StockNewsTrends full disclosure is to be read and fully understood before using StockNewsTrends website, or joining StockNewsTrends' email or text list. By viewing StockNewsTrends's website and/or reading StockNewsTrends email or text newsletter you are agreeing to StockNewsTrends's full disclosure which can be read at https://stocknewstrends.com/disclosure/ Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. StockNewsTrends (stocknewstrends . com) is owned by TD Media LLC, a limited liability company.  Pursuant to an agreement between TD Media LLC and Awareness Consulting Network LLC, TD Media LLC has been hired for a period beginning on 08/18/2024 and ending on 08/19/2024 to publicly disseminate information about (NNVC:US) via digital communications. We have been paid fifteen thousand dollars USD. We own zero shares of (NNVC:US).

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice